Are Omicron-specific vaccines any better than original jabs? What early tests show

Published on Feb 16, 2022 08:26 AM IST
  • Last month, Pfizer and Moderna announced that they have started clinical trials of their Omicron-specific vaccine shots.
The study found no differences between monkeys receiving a conventional booster or one specifically targeting the Omicron variant(Matt Slocum/AP Photo/picture alliance )
The study found no differences between monkeys receiving a conventional booster or one specifically targeting the Omicron variant(Matt Slocum/AP Photo/picture alliance )
Written by Sharmita Kar | Edited by Sohini Goswami

Early animal studies conducted by scientists across the world have found that Omicron-specific boosters of coronavirus vaccine do no better job than the previously available ones in preventing the infection. The Omicron variant of Covid-19, which is still globally dominant, is the highest transmissible strain so far.

A lot of research has been going on to find out if a third dose of the vaccine is good enough to build immunity against Omicron. Leading vaccine makers Pfizer and Moderna earlier also announced that they have started clinical trials of their Omicron-specific vaccine shots.

“What we’re seeing coming out of these preclinical studies in animal models is that a boost with a variant vaccine doesn’t really do any better than a boost with the current vaccine,” said David Montefiori, director of the Laboratory for AIDS Vaccine Research and Development at Duke University Medical Center in Durham, North Carolina, speaking to Nature journal.

A report in the journal said most of the early studies involved a small batch of animals and all of them hinted that a customised booster shot of the vaccine will not change anything against Omicron. These studies are yet to be peer reviewed.

According to the report, one study examined immune responses of rhesus macaques (a breed of monkeys), just eight primates, with two doses of Moderna's original vaccine and one booster shot of either the same dose or an Omicron-specific version. Researchers found the monkeys boosted with either vaccine showed a broad antibody response against all variants of concern, including Omicron.

However, the study examined responses up to only four weeks, meaning it is not clear as to how long the efficacy of the vaccine will last.

In another study, scientists examined a ‘replicating RNA’ vaccine in mice. They were given three doses of the replicating RNA vaccine – two doses based on the ancestral SARS-CoV-2 strain followed by a single Omicron-specific booster – made by HDT Bio in Seattle, Washington, the report said.

While the third dose of Omicron-specific vaccine did not provide better results, a response was seen in mice that were administered one dose of the vaccine based on ancestral strain, followed by two doses of the variant-specific vaccine.

“There are important questions that still need to be addressed. Hopefully Pfizer and Moderna’s Omicron studies in humans will do that," Montefiori told the journal.

Close Story

Less time to read?

Try Quickreads

  • Several Public health experts have warned that the H1N1 virus along with Covid-19 could cause a "twindemic" in the Himalayan country. (Representation purpose)

    Nepal battles 'Twindemic' as swine flu wreaks havoc amid rising Covid cases

    According to the World Health Organisation's Global Influenza Surveillance, at least 57 cases of H1N1 infection have been reported since June 6 and the infection of 55 cases of AH3 virus also known as Hong Kong flu have been also reported in the same period.

  • Tesla and SpaceX founder and chief engineer Elon Musk.

    Elon Musk seeks to question Twitter employees who check bot accounts

    Elon Musk's legal team is demanding that Twitter Inc turn over the names of employees responsible for calculating what percentage of the social media site's users are bot and spam accounts, according to a source familiar with the matter. Twitter and Musk are in the discovery phase of the lawsuit and readying for a trial scheduled to begin Oct. 17 in Delaware. Twitter and a lawyer for Musk declined to comment.

  • Ousted Sri Lankan President Gotabaya Rajapaksa. (AP Photo/Eranga Jayawardena, File)

    Thailand allows Rajapaksa to temporarily stay in country, but has one condition

    Thailand foreign minister Don Pramudwinai said that the Sri Lankan government led by President Ranil Wickremesinghe did not object to Gotabaya Rajapaksa's visit to Thailand. However, the former president need to figure out his accommodation himself as the Thai government has refused to make any arrangements for the same.

  • Tourists go through pre-departure formalities at the Sanya Phoenix airport as stranded holidaymakers prepare to leave the Covid-hit resort city of Sanya on Hainan Island in China. (Photo by Str/AFP)

    Global Covid deaths drop by 9%, Omicron subvariant BA.5 remains dominant: WHO

    The WHO said that the Omicron subvariant BA.5 continues to remain dominant worldwide, contributing nearly 70 per cent to all virus sequences shared with the world's biggest publicly available virus database. It added that other Omicron subvariants such as BA.4 and BA.2, appear to be decreasing in prevalence as BA.5 takes control.

  • A view of Hangzhou city in China’s eastern Zhejiang province. (AFP)

    First special business flight with over 100 Indian traders lands in China

    A special flight with 107 Indian traders landed in the eastern Chinese city of Hangzhou on Tuesday, carrying many who were stuck in India since 2020 despite business interests in China because of the restrictions imposed by Beijing on international travel to contain Covid-19. This particular group of Indian merchants boarded the special China Southern Airlines flight from New Delhi and landed in Hangzhou, the capital of Zhejiang province, on Tuesday.

Story Saved
Saved Articles
My Reads
Sign out
New Delhi 0C
Thursday, August 11, 2022
Start 15 Days Free Trial Subscribe Now